Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 92 Cash Ratio is 1.08 as of Mar. 2026, which is 227% above its 10-year median of 0.33. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr209.27 (Modestly Overvalued). Among 1,384 Biotechnology companies, Alk-Abello AS ranks worse than 72.4% on this metric.
Alk-Abello AS has a Cash Ratio of 1.08. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Alk-Abello AS's Cash Ratio or its related term are showing as below:
CHIX:ALKBc'
s Cash Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.33 Max: 1.08
Current: 1.08
During the past 13 years, Alk-Abello AS's highest Cash Ratio was 1.08. The lowest was 0.10. And the median was 0.33.
CHIX:ALKBc's Cash Ratio is ranked worse than 72.4% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs CHIX:ALKBc: 1.08
Alk-Abello AS (CHIX:ALKBc) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Alk-Abello AS Cash Ratio Related Terms
Alk-Abello AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a Cash Ratio of 1.08 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alk-Abello AS and its competitors. This is 227% above median its historical median of 0.33. Over the past decade, Alk-Abello AS's Cash Ratio has ranged from 0.10 to 1.08. According to the industry distribution chart, Alk-Abello AS ranks #1002 out of 1384 companies in the Biotechnology industry, placing it in the top 72.4%.
Is Alk-Abello AS's Cash Ratio too high?
Alk-Abello AS's current Cash Ratio of 1.08 is 227% above median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.08. The Biotechnology industry median Cash Ratio is 2.94. Alk-Abello AS's value of 1.08 is 63.3% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #1002 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #1002 out of 1384 companies for Cash Ratio. This places Alk-Abello AS in the lower half of its industry. The industry median Cash Ratio is 2.94. Alk-Abello AS's value of 1.08 is 63.3% below this benchmark. Historically, Alk-Abello AS's own Cash Ratio has ranged from 0.10 to 1.08 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 2.94, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Cash Ratio of 1.08 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Cash Ratio is 1.08, which is 227% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr209.27, compared to a current price of kr256.30 — trading 22.5% above its estimated fair value. The current Cash Ratio is 1.08, which is 227% above median its 10-year median of 0.33 and 63.3% below the Biotechnology industry median of 2.94. Alk-Abello AS's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Cash Ratio is 1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 22.5% above its estimated GF Value™ of kr209.27.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
Cash Ratio: 1.08 (227% above median its 10-year median of 0.33)
GF Value™: kr209.27 vs. price of kr256.30 (22.5% above fair value)
Industry Position: 63.3% below the Biotechnology median (#1002 of 1384)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
